Celyad Oncology SA
CLYYF
$0.65
-$0.03-4.41%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 31.05% | 63.84% | 73.22% | 70.00% | -- |
| Total Depreciation and Amortization | -49.51% | -38.72% | -28.34% | 11.50% | -- |
| Total Amortization of Deferred Charges | 19.79% | 17.43% | 14.63% | 14.63% | -- |
| Total Other Non-Cash Items | 87.69% | -98.19% | -97.38% | -102.25% | -- |
| Change in Net Operating Assets | 97.27% | 74.34% | 47.48% | -24.14% | -- |
| Cash from Operations | 62.62% | 55.53% | 49.71% | 17.33% | -- |
| Capital Expenditure | -- | 52.98% | -75.94% | -330.16% | -- |
| Sale of Property, Plant, and Equipment | -98.88% | -98.45% | -98.02% | 5.49% | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -238.20% | -4,100.00% | -395.40% | -234.68% | -- |
| Cash from Investing | -125.38% | -110.94% | -110.17% | -102.14% | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -15.17% | 52.58% | 72.47% | 68.64% | -- |
| Issuance of Common Stock | -- | 0.00% | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 31,400.00% | 32.78% | -44.14% | -71.98% | -- |
| Cash from Financing | -68.15% | 13.96% | 246.79% | 208.31% | -- |
| Foreign Exchange rate Adjustments | -330.00% | -135.48% | -100.00% | -103.62% | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 48.34% | 89.17% | 113.52% | 61.66% | -- |